Voyager Therapeutics Licenses Novel Gene Therapy Capsids From the California Institute of Technology
Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), recently announced a co-exclusive worldwide license agreement with the California Institute of Technology (Caltech) related to novel adeno-associated virus (AAV) capsids. The license agreement covers all fields of use and includes novel AAV capsids that have demonstrated enhanced blood-brain barrier penetration for the potential treatment of CNS diseases following systemic administration of an AAV gene therapy vector.
Under the agreement, Voyager agreed to purchase co-exclusive rights to the novel AAV capsids, intellectual property and related technology. Voyager will further compensate Caltech upon achievement of certain development and regulatory milestones and share royalties upon the potential commercial launch of products utilizing the capsids included in the agreement.
“The agreement announced today with Caltech expands Voyager’s portfolio of AAV capsids to include novel capsids with enhanced blood-brain barrier penetration and CNS targeting,” said Dinah Sah, Ph.D., senior vice president of neuroscience at Voyager Therapeutics. “We are excited to be able to partner with Dr. Ben Deverman and Professor Viviana Gradinaru at Caltech to continue to advance this technology which, in preclinical studies, generated AAV variants that broadly transduced the CNS with enhanced efficiency after intravenous injection.”
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the CNS. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Total Page Views: 1207
